- Home
- NUWE vs ENVB Comparison
NUWE vs ENVB Comparison
Compare NUWE & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- ENVB
- Stock Information
- Founded
- NUWE 1999
- ENVB 1994
- Country
- NUWE United States
- ENVB United States
- Employees
- NUWE N/A
- ENVB N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- ENVB Health Care
- Exchange
- NUWE Nasdaq
- ENVB Nasdaq
- Market Cap
- NUWE 2.9M
- ENVB 3.0M
- IPO Year
- NUWE N/A
- ENVB N/A
- Fundamental
- Price
- NUWE $2.69
- ENVB $6.00
- Analyst Decision
- NUWE
- ENVB Strong Buy
- Analyst Count
- NUWE 0
- ENVB 1
- Target Price
- NUWE N/A
- ENVB $10.00
- AVG Volume (30 Days)
- NUWE 139.8K
- ENVB 121.7K
- Earning Date
- NUWE 11-12-2025
- ENVB 11-13-2025
- Dividend Yield
- NUWE N/A
- ENVB N/A
- EPS Growth
- NUWE N/A
- ENVB N/A
- EPS
- NUWE N/A
- ENVB N/A
- Revenue
- NUWE $8,318,000.00
- ENVB N/A
- Revenue This Year
- NUWE $6.53
- ENVB N/A
- Revenue Next Year
- NUWE $51.63
- ENVB N/A
- P/E Ratio
- NUWE N/A
- ENVB N/A
- Revenue Growth
- NUWE N/A
- ENVB N/A
- 52 Week Low
- NUWE $2.72
- ENVB $5.62
- 52 Week High
- NUWE $175.98
- ENVB $96.30
- Technical
- Relative Strength Index (RSI)
- NUWE 36.37
- ENVB 68.44
- Support Level
- NUWE $3.01
- ENVB $5.62
- Resistance Level
- NUWE $4.00
- ENVB $8.61
- Average True Range (ATR)
- NUWE 0.26
- ENVB 0.51
- MACD
- NUWE -0.01
- ENVB 0.58
- Stochastic Oscillator
- NUWE 2.99
- ENVB 64.11
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.